Unlike in metastatic disease, recently published data investigating the utility of adding anti-PD-1 or anti-PD-L1 checkpoint inhibition to chemoradiation for locally advanced disease have not been shown to universally improve outcomes [7,29]. Here, CD274 is linked to metastatic neoplasm.